Target intelligence / Profile preview

Microbial anti-inflammatory molecule (MAM) (MAM)

Target
MAM
Molecular classification
Microbial protein [1, 2, 6, 15], Effector protein [15], Anti-inflammatory protein [1, 2, 3, 4, 5, 6, 15], Other [15, 17]
01

Overview

The Microbial anti-inflammatory molecule (MAM) is a 15 kDa protein produced by the commensal gut bacterium Faecalibacterium prausnitzii, which is one of the most abundant species in the healthy human microbiota [2, 6, 15]. MAM serves as a key effector molecule that mediates the anti-inflammatory effects of the bacterium, primarily by inhibiting the NF-kappaB signaling pathway in intestinal epithelial cells [1, 2, 3, 15]. This inhibition leads to a significant reduction in the production of pro-inflammatory cytokines, such as Interleukin-8 (IL-8), and helps to suppress Th1, Th2, and Th17 immune responses [4, 6, 11]. Furthermore, MAM plays a crucial role in maintaining and restoring the intestinal barrier by upregulating tight junction proteins like Zonula occludens-1 (ZO-1), which prevents the translocation of pathogens and toxins [1]. In clinical contexts, a depletion of Faecalibacterium prausnitzii and its associated MAM protein is a hallmark of dysbiosis in patients with Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases (IBD) [2, 5, 6, 11]. Research has also linked MAM deficiency to metabolic disorders such as type 2 diabetes and potentially neurodegenerative conditions like Parkinson's disease [1, 15]. Therapeutic strategies currently under investigation include the administration of recombinant MAM protein, MAM-derived peptides, or engineered "live biotherapeutic" probiotics, such as Lactococcus lactis, designed to deliver the MAM gene directly to the intestinal mucosa [2, 3, 4, 6]. These approaches aim to restore gut homeostasis and alleviate chronic inflammation by mimicking the natural protective mechanisms of the commensal microbiota [5, 15].

Other names
MAM proteinFaecalibacterium prausnitzii anti-inflammatory proteinFaecalibacterium duncaniae anti-inflammatory proteinMicrobial anti-inflammatory molecule 1
02

Mechanism of action

Inhibition of the NF-kappaB signaling pathway and upregulation of tight junction proteins (e.g., ZO-1) to restore intestinal barrier integrity and reduce pro-inflammatory cytokine secretion [1, 2, 3, 6, 15].

03

Biological functions

Immune response [1, 2, 3, 4, 15]Inhibition of NF-kappaB pathway [1, 2, 3, 4, 6, 15]Regulation of intestinal barrier function [1, 10, 11]Inhibition of pro-inflammatory cytokine production [4, 6, 11]Signal transduction [1, 2, 6]
04

Disease associations

Inflammation [1, 2, 3, 4, 5, 11, 15]Crohn's disease [2, 5, 6, 11]Ulcerative colitis [5, 11]Diabetes mellitus [1, 6, 15]Infection [15]Other [15]
05

Safety considerations

Protein stability in the gastrointestinal tract [2]Potential immunogenicity of microbial proteins [15]Strain-dependent variability in protein activity [4]Challenges in effective mucosal delivery [2, 3, 4, 6]
06

Interacting drugs

Recombinant MAM protein [1, 4]

2 more in the full profile.

07

Biomarkers

Faecalibacterium prausnitzii abundance [2, 3, 5, 6, 11]Interleukin-8 (IL-8) levels [4, 6, 11]Zonula occludens-1 (ZO-1) expression [1]NF-kappaB activation levels [2, 3, 4, 6]

Beyond the preview

Go deeper on Microbial anti-inflammatory molecule (MAM) (MAM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbial anti-inflammatory molecule (MAM) (MAM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call